Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells)

Carcinogenesis

Volumn 18, Issue 2, 1997, Pages 303-313

  Styles, J A ^a   Davies, A ^a   Davies, R ^a   White, I N H ^a   Smith, L L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 HYDROXYTOREMIFENE; CLASTOGEN; CLOMIFENE; COMPLEMENTARY DNA; CYTOCHROME P450; DIETHYLSTILBESTROL; DROLOXIFENE; EPIDERMAL GROWTH FACTOR; EPOXIDE HYDROLASE; GLYCEROL FORMAL; TAMOXIFEN; TOREMIFENE; VINBLASTINE;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; LYMPHOBLASTOID CELL LINE; MICRONUCLEUS TEST; MITOSIS INHIBITION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANEUPLOIDY; ANIMALS; ANTICARCINOGENIC AGENTS; CELL LINE; CELL NUCLEUS; CLOMIPHENE; FEMALE; HUMANS; LIVER; LYMPHOCYTES; MICRONUCLEUS TESTS; RATS; RATS, WISTAR; TAMOXIFEN; TOREMIFENE; TRANSFECTION;

EID: 0031408922     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.2.303     Document Type: Article

References (43)

1. Gusberg, S.B. (1990) Tamoxifen for breast cancer: associated endometrial cancer. Cancer, 65, 1463-1464.
2. Fisher, B., Constantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP). J. Natl Cancer Inst., 86, 527-537.
3. Seachrist, L. (1994) Restating the risks of tamoxifen, Science, 263, 910-911.
4. Marshall, E. (1994) Tamoxifen: hanging in the balance. Science, 264, 1524-1527
5. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T. and Wilking, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl Cancer Inst., 87, 645-651.
6. Fornander, T. et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, i, 117-119.
7. Greaves, P., Goonetilleke, R., Nunn, G, Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
8. Hard, G. Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. and Williams, G.M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
9. Tucker, M.J., Adam, H.K. and Patterson, J.S. (1984) Tamoxifen. In Laurence, D.R., McLean, A.E.M. and Weatherall, M. (eds), Safety Testing of New Drugs. Academic Press, New York, NY, pp. 125-161.
10. Rattel, B., Löser, R., Dahmer, E.G., Liehn, H.D. and Seibel, K. (1987) Comparative toxicology of droloxifene (3-OH tamoxifen) and tamoxifen: hepatocellular carcinomas produced by tamoxifen. Proceedings of the Biennial International Breast Cancer Research Conference, Miami. Abstract F18.
11. Dahmer, E. and Rattel, B. (1994) Unlike tamoxifen, droloxifene produces no hepatic tumours in the rat. Onkologie, 17, 6-16.
12. Williams, G.M., Iatropoulos, M.J. and Hard, G.C. (1992) Long-term prophylactic used of tamoxifen: is it safe? Eur. J. Cancer Prevent., 1, 386-387.
13. Hirsimaki, P., Hirsimaki, Y., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1 year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
14. Ghia, M. and Mereto, E. (1989) Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett., 46, 195-202.
15. Yager, J.D., Roebuck B.D., Paluszcyk, T.L. and Memoli, V.A.(1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis, 7, 2007-2014.
16. Yager, J.D. and Shi, Y.E. (1991) Synthetic estrogens and tamoxiten as promoters of hepatocarcinogenesis. Prevent. Med., 20, 27-37.
17. Carthew, P., Martin, E.A., White, I.N.H., De Matteis, F., Edwards, R.E., Dorman, B.M., Heydon, R.T. and Smith, L.L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547.
18. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
19. Martin, E.A., Turtletaub, K.W., Heydon, R., Davies, A., White, I.N.H. and Smith, L.L. (1995) Characterisation of tamoxifen induced DNA adducts formed in rat liver. Toxicologist, 15, 152 (abstract 811).
20. Han, X. and Liehr, J.G. (1990) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
21. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1993) Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
22. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
23. Mani, C. and Kupfer, D. (1991) Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51, 6052-6058.
24. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. and Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9.
25. Crofton-Sleigh, C., Doherty, A., Ellard, S., Parry, E.M. and Venitt, S. (1993) Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. Mutagenesis, 8, 363-372.
26. Sargent, L.M., Dragan, Y.P., Bahnub, N., Wiley, J.E., Sattler, C., Schroeder, P., Sattler, G.L., Jordan, V.C. and Pitot, H.C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54, 3357-3360.
27. Styles, J.A., Davies, R. and Smith, L.L.(1995) Comparison of clastogenic effects induced in rats by tamoxifen and some of its analogues. Toxicologist, 15, 82 (abstract 432).
28. Sargent, L.M. et al. (1996) Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis, 17, 1051-1056.
29. Styles, J.A., Davies, R., Martin, E.A., White, I.N.H. and Smith, L.L. (1996) Tamoxifen causes somatic gene mutations, DNA adducts and hyperplasia in the livers of Big Blue transgenic F344 rats. Toxicologist, 30, 161 (abstract 823).
30. Lim, C.K., Yuan, Z.-X., Lamb, J.H., White, I.N.H., De Matteis, F. and Smith, L.L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis, 15, 589-593.
31. Vogel, C.L., Shemano, I., Schoenfelder, J., Gams, R.A. and Green, M.R. (1993) Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol., 11, 345-350.
32. Valavaara, R. et al. (1988) Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur. J. Cancer Clin. Oncol., 24, 785-790.
33. Scott, D., Danford, N., Dean, B.J. and Kirkland, D. (1990) Metaphase chromosome aberration assays in vitro. In Kirkland, D.J. et al. (eds) Basic Mutagenicity Tests: UKEMS Recommended Procedures. UKEMS Subcommittee on Guidelines for Mutagenicity Testing Report. Part I Revised. Cambridge University Press, Cambridge, UK, pp. 62-86.
34. Crespi, C.L, Sierras, G.M. and Penman, B.O.W. (1987) The induction of aneuploidy by nitrogen mustard in a human lymphoblastoid cell line. Mutat. Res., 190, 69-76.
35. Van Prooijen-Knegt, A.C. et al. (1982) Spreading and staining of human metaphase chromosomes on aminoalkysilane-treated glass slides. Histochem. J., 14, 333-344.
36. Kirkland, D.J. et al. (eds) Basic Mutagenicity Tests: UKEMS Recommended Procedures. UKEMS Sub-committee on Guide lines for Mutagenicity Testing Report. Part I Revised. Cambridge University Press, Cambridge, UK.
37. IARC Monographs (1987) Oestrogens, progestins and combinations. IARC Monogr., 7, 273-278.
38. Pitot, H. (1989) Progression: the terminal stage in carcinogenesis. Jpn. J. Cancer Res., 80, 599-607.
39. Metzler, M. and Schiffmann, D. (1991) Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens. Am. J. Clin. Oncol., 14 (suppl. 2), 30-35.
40. Kärki, N.T. and Kärki, T. (1986) Cytogenetic effects of a novel antiestrogen toremifene FC-1157a: a comparison with diethylstilbestrol and tamoxifen. Arch. Toxicol., suppl. 9, 291.
41. Ames, B.N. and Gold, L.S. (1991) Mitogenesis, mutagenesis and animal cancer tests. In Butterworth, B.E., Slaga, T.J., Farland, W. and McClain, M. (eds), Chemically Induced Cell Proliferation: Implications for Risk Assessment. Wiley-Liss, New York, NY, pp. 1-20.
42. Cohen, S.M. and Ellwein, L.B. (1990) Cell proliferation in carcinogenesis. Science, 249, 1007-1011.
43. 32P-postlabelling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.